Idexx Laboratories Posts $278.4M Q1 Profit, Boosts Annual Revenue Outlook to $4.68B–$4.76B
Idexx Laboratories earned $278.4 million in Q1 net profit, delivering $3.47 earnings per share versus the $3.42 consensus and surging revenue 14% to $1.14 billion. The company lifted full-year revenue guidance to $4.68–$4.76 billion, signaling confidence in ongoing diagnostic testing demand.
1. Q1 Financial Results
Idexx Laboratories reported net profit of $278.4 million in the first quarter, translating to $3.47 earnings per share compared with the $3.42 consensus and up from $2.96 a year earlier.
2. Revenue Performance Drivers
Revenue climbed 14% year-over-year to $1.14 billion, driven by higher diagnostic testing volumes and increased clinical visit frequency across North America and international markets.
3. Guidance Raise
Management raised full-year revenue guidance to a range of $4.68 billion to $4.76 billion, reflecting strong backlog and sustained demand for its animal diagnostic products and services.
4. Analyst and Market Reaction
Analysts revised estimates upward following the earnings beat and guidance boost, and shares rallied as investors responded positively to the company’s execution and growth outlook.